These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Gajewski TF Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5256-61. PubMed ID: 17875753 [TBL] [Abstract][Full Text] [Related]
44. Melanoma vaccines: in search of a clinical paradigm. Storkus WJ Melanoma Res; 2007 Jun; 17(3):137-8. PubMed ID: 17505258 [No Abstract] [Full Text] [Related]
45. [Prognosis assessment in malignant melanoma: relevance for decisions regarding adjuvant therapies and after care]. Sterry W J Dtsch Dermatol Ges; 2008 Mar; 6(3):171. PubMed ID: 18315620 [No Abstract] [Full Text] [Related]
46. Getting under the skin with melanoma vaccines. Bonn D Lancet; 1996 Aug; 348(9024):396. PubMed ID: 8709743 [No Abstract] [Full Text] [Related]
47. Skin diseases with high public health impact. Melanoma. Murphy GM Eur J Dermatol; 2007; 17(6):559-62. PubMed ID: 17951156 [No Abstract] [Full Text] [Related]
49. Immune and gene therapy for melanoma, and the immunobiology of melanoma. Smith KJ; Skelton H Int J Dermatol; 1999 Jul; 38(7):490-508. PubMed ID: 10440277 [No Abstract] [Full Text] [Related]
54. Follow-up of melanoma patients: the need for evidence-based protocols. Francken AB; Hoekstra HJ Ann Surg Oncol; 2009 Apr; 16(4):804-5. PubMed ID: 19189190 [No Abstract] [Full Text] [Related]
55. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917 [TBL] [Abstract][Full Text] [Related]
57. [Re: innovative therapeutic approaches in melanoma]. Vereecken P; Awada A; Devriendt D; Laporte M; Heenen M; Salès F; Cappello M Rev Med Brux; 2004 Dec; 25(6):S 542. PubMed ID: 15688894 [No Abstract] [Full Text] [Related]
58. Therapeutic vaccines in solid tumours: can they be harmful? Eggermont AM Eur J Cancer; 2009 Aug; 45(12):2087-90. PubMed ID: 19477117 [TBL] [Abstract][Full Text] [Related]
59. Important first chance. Avery JK J Ark Med Soc; 2007 May; 103(11):269. PubMed ID: 17539456 [No Abstract] [Full Text] [Related]
60. Melanoma: an under-recognized cancer threat. Esper P Oncology (Williston Park); 2009 Jul; 23(8 Suppl):22. PubMed ID: 19860038 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]